Drug intelligence / Profile preview

navepdekinra

Development stage: Phase 2
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Oral

Overview

Navepdekinra is an oral small-molecule interleukin‑17A (IL‑17A) inhibitor being developed as a next‑generation anti‑inflammatory therapy, primarily for plaque psoriasis and related IL‑17–driven diseases. It selectively inhibits IL‑17A signaling, a key cytokine in Th17‑mediated inflammation implicated in psoriasis pathogenesis, thereby reducing keratinocyte activation and inflammatory cascades in skin. Navepdekinra (also referenced as DC‑806, LY4100504, S 011806, Example 210) has been characterized preclinically as a potent IL‑17A inhibitor with anti‑inflammatory activity and has advanced into phase 2 clinical development in plaque psoriasis before discontinuation of development in that indication by its sponsors.[1][3][5][7][9][17]

Other names: navepdekinra

Targets

IL-17A (Interleukin-17A)

Beyond the preview

Go deeper on navepdekinra.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on navepdekinra.

Explore the full profile